Reduction of EGF receptor synthesis by antisense RNA vectors  by Hunts, John et al.
Volume 206, number 2 FEBS 4082 October 1986 
Reduction of EGF receptor synthesis by antisense RNA 
vectors 
John Hunts*, Glenn Merlino, Ira Pastan and Nobuyoshi Shimizu*+ 
*Dept of Molecular and Cellular Biology, University of Arizona, Tucson, AZ, USA, Laboratory of Molecular Biology, 
NCI, Bethesda, MD, USA and +Dept of Molecular Biology, Keio University School of Medicine, Tokyo, Japan 
Received 30 July 1986 
An association has been observed between squamous cell carcinomas and elevated EGF receptor levels. The 
approach taken here to analyze this problem was to construct vectors which express antisense RNA for 
the EGF receptor. The plasmid vector used was derived from pSV2-neo, which is readily selectable. Three 
EGF receptor cDNA fragments, a 5’-, a middle and a 3’-region were tested for differences in efficiency as 
antisense RNA. The results suggest hat the 5’-fragment was the most efficient. 
antisense RNA EGF receptor (Squamous cell carcinoma) 
1. INTRODUCTION 
The EGF receptor (EGFR) gene has been im- 
plicated as a proto-oncogene by both qualitative 
[l] and quantitative evidence [2-41. One technique 
which may prove useful in studying EGFR func- 
tion and activity is the use of complementary or 
antisense RNA. Antisense RNA has been used with 
some success for the thymidine kinase (TK) gene 
and an actin gene [5,6]. By reversing the direction 
of the gene of interest relative to its promoter, the 
opposite strand of DNA will be transcribed, 
generating a complementary antisense RNA. This 
antisense RNA can then hybridize with the sense 
RNA to inhibit its translation into protein. In the 
case of the antisense RNA which is generated in the 
nucleus, the hybridization is thought to inhibit 
gene expression by preventing RNA transport out 
of the nucleus [6]. 
Elevated EGFR levels have been associated with 
squamous cell carcinomas [2-41. Furthermore, at 
least 3 mechanisms have the potential to increase 
the level of EGFR on the cell surface [7]. To 
understand better what role(s) elevated EGFR 
levels play in the transformation process, antisense 
EGFR-RNA vectors were tested for efficiency of 
EGFR inhibition. Three different fragments of the 
EGFR cDNA were tested for antisense RNA, a 
5’-, a middle and a 3 ‘-fragment. The 5’-fragment 
was observed to be the most efficient in reducing 
EGFR levels in a squamous cell carcinoma cell 
line. 
2. MATERIALS AND METHODS 
2.1. Recombinant DNA 
Techniques and procedures were performed as 
described [S]. The parent plasmid used was 
pSV2neo [9], which allows resistance to the an- 
tibiotic G-41 8 (Gibco). 
2.2. Ceil culture 
The squamous cell carcinoma cell line NA [lo] 
was maintained at 37°C in DMEM supplemented 
with 10% fetal calf serum, 100 units/ml penicillin 
and 100 pg/ml streptomycin in the presence of 
10% coz. 
2.3. DNA transfection 
The vector DNA was introduced into NA cells 
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by calcium phosphate-DNA co-precipitation [ 111. 
Briefly, 5 x lo5 cells plated the previous night in 
90 mm dishes were exposed to precipitated DNA 
(20pg/plate) for 24 h at 37°C. The next day the 
medium was changed and after 48 h of the initial 
DNA exposure, the cells were placed under G-418 
selection. Single colonies appeared approx. 14 days 
later and were isolated with cloning rings. 
2.4. EGF binding 
Confluent cells in 24 well dishes (2 cm*) were in- 
cubated in ice (O’C) for 2 h in the presence of 
100 ng/ml ‘*‘I-EGF (plus 1 pg/ml unlabeled EGF 
for non-specific binding) in a total volume of 
0.2 ml of EBSS, pH 7.4, 5 mM Hepes and 
1 mg/ml BSA. 
3. RESULTS 
Initially, a general purpose vector was con- 
structed using the pSV2neo plasmid [9]. The 
pSV2neo plasmid was chosen because it has a 
selectable marker, neo, which gives cells resistance 
to the drug G-418. Fig.1 shows the outline of the 
construction of the expression vector PEN. A Hin- 
dII1 site was first deleted from pSV2neo. This 
change did not disrupt the neo gene activity. An 
EcoRI-BumHI 375 bp fragment from pBR322 was 
then added to this plasmid. An SV40 poly(A) site 
from pMTVdhfr [ 121 was put into the filled EcoRI 
site, generating PEN. The PEN vector has 3 unique 
restriction sites ClaI, HindIII, and BarnHI. 
The vector PEN was then used to construct anti- 
sense-EGFR vectors. Fig.2a shows the vectors 
which were constructed. All the vectors contain the 
AEV LTR as a promoter [ 131 inserted in the Hin- 
dII1 site of PEN. Three fragments from the EGFR 
cDNA were chosen (fig.2a). A 717 bp PvuII-ClaI 
5 ‘-fragment was used [14] and filled in and in- 
serted in the filled C/a1 site of PEN, generating 
pERR5. Likewise, a middle BumHI fragment of 
1032 bp was isolated [ 141 and filled in and inserted 
in PEN at the filled CIuI site, giving rise to 
pERRM. Similarly, a 3 ’ -ClaI fragment of 1076 bp 
was isolated [14] and inserted in the ClaI site of 
PEN, giving pERR3. All EGFR inserts were 
selected for in the opposite orientation to the pro- 
moter relative to the normal gene (fig.2b). 
The vectors were introduced into NA cells, 
EGFR hyperproducers, by calcium phosphate- 
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Fig. 1. Construction of PEN. pSV2neo [9] was modified 
with pBR322 to contain 3 unique restriction sites. The 
EcoRI-BgfiI fragment from pMTVdhfr [ 1 l] contains the 
polyadenylation site and intron for the small T antigen 
of SV40. Restriction enzymes are: B, BumHI; C, ClaI; 
E, EcoRI; H, HindHI; P, Z-W. The dark regions are 
derived from pBR322, the stippled regions from SV40 
and the hatched box is the neo gene. 
DNA precipitation [ll]. Cells possessing the in- 
tegrated vector were then selected for by using the 
drug G-418 [9]. Single colonies were isolated using 
cloning rings. These G-418 resistant colonies were 
then checked for EGF binding relative to the 
parental NA cells. The results of the binding assays 
from several different clones selected from 
pERR5, pERRM and pERR3 are shown in fig.3. 
The results indicate that pERR5, containing the 
5 ‘-end of the EGFR cDNA was the most efficient 
at inhibiting EGFR expression. A decrease of up to 
52% was seen in pERR5 clone 5-l (fig.3a). The 
average for the pERR5 clones was a reduction of 
EGF binding by 26% (fig.3b). The other vectors 
Volume 206, number 2 FEBS LETTERS October 1986 
A 
EGFR-M--pERRM 
Fig.2. Antisense EGFR-RNA vectors. (A) Three 
antisense vectors were constructed with the EGFR 
cDNA fragment oriented in the opposite direction as to 
the retroviral AEVLTR promoter. The names of the 
vectors were pERR5, pERRM and pERR3, which 
contain 5 ’ -, M and 3’-fragments, respectively. (B) 
EGFR cDNA fragments used for each of the vectors 
with the dark region showing the transmembrane 
domain (for a complete description of EGFR cDNAs see 
t1411. 
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Fig.3. EGF binding. (A) Clones isolated using each of 
the three vectors were tested for EGF binding relative to 
the parental cell line NA (NA binding shown as 
horizontal line). (B) The average percent change in EGF 
binding for the three vectors relative to NA. 
pERRM and pERR3 showed little or no reduction 
in EGF binding. These results suggest that the 
5 ‘-fragment of the EGFR cDNA is the most effi- 
cient for antiserum-RNA inhibition of EGFR gene 
expression in NA. 
4. DISCUSSION 
The squamous cell carcinoma cell line used for 
testing these vectors, NA, has a 20-30-fold EGFR 
gene amplification [IO] accompanied by a similar 
high level of EGFR mRNA [lo]. This suggests that 
in order for the EGFR levels to be reduced more in 
NA, a larger amount of EGFR antisense RNA 
must be produced. We are presently testing an 
amplification vector [6] for this. The antisense 
RNA is linked to the mRNA for the dihydrofolate 
reductase (dhfr) gene by inserting the antisense 
gene between dhfr and its poly(A) site, generating 
a bi-functional mRNA. Reducing the EGFR levels 
in NA could change some properties of NA and 
give more information as to what effect high 
EGFR levels have in these transformed cells, such 
as changing the growth characteristics. Similarly, 
if the endogenous EGFR gene expression could be 
reduced to zero, rearranged or altered EGFR genes 
could then be introduced to characterize better the 
receptor function. 
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